Pharmaceuticals, Biotechnology & Life Sciences

Henan Lingrui Pharmaceutical’s senior‑management resignations spark new analyst scrutiny as the 600285 stock stays flat amid leadership changes.

Trulieve Cannabis Corp: stock dips amid regulatory uncertainty, but medical‑cannabis focus keeps investors hopeful for future growth.

FDA rejects Vanda’s HETLIOZ® jet‑lag application, citing insufficient real‑world evidence, but the company remains poised to address concerns and seek approval.

Explore Erasca Inc.’s volatile stock, analyst “overweight” support, and upcoming J.P. Morgan Healthcare Conference to gauge future upside and risks.

Akanda Corp, a medicinal‑grade cannabis cultivator, faces volatility yet eyes U.S. regulatory shifts for growth.

KalVista Pharmaceuticals sees a major boost with EKTERLY’s Japan approval—yet investors face volatility, a negative P/E, and high valuation risks. Read the full story.

Explore Harmony Biosciences’ strategy and market outlook—discussed at the JP Morgan Healthcare Conference—to gauge its sleep‑wake therapeutics upside and analyst sentiment for investors.

Discover how Zomedica Corp’s new VETGuardian PLUS™ Monitor could reshape pet‑care tech—while its financials reveal the tight trade‑off between innovation and growth.

Upstream Bio’s verekitug, a Phase 2 asthma treatment, makes a strong pitch at the J.P. Morgan Healthcare Conference, hinting at breakthrough prospects for severe respiratory disorders.

Merck’s Q4 earnings, analyst sentiment, and Big Pharma’s 2025 resurgence spotlight how a diversified drug portfolio and regulatory shifts drive investor confidence.